Petrella M, Borruto A, Curti L, Domi A, Domi E, Xu L
Neuropharmacology. 2024; 248:109866.
PMID: 38364970
PMC: 11094429.
DOI: 10.1016/j.neuropharm.2024.109866.
Higginbotham J, Markovic T, Massaly N, Moron J
Front Syst Neurosci. 2022; 16:1014768.
PMID: 36341476
PMC: 9628214.
DOI: 10.3389/fnsys.2022.1014768.
Wang F, Shen W, Cai Y, Zhang X, Du H, Lai M
Front Psychiatry. 2022; 13:983595.
PMID: 36276332
PMC: 9583165.
DOI: 10.3389/fpsyt.2022.983595.
Neve J, Barlow T, Tourwe D, Bihel F, Simonin F, Ballet S
RSC Med Chem. 2021; 12(6):828-870.
PMID: 34223156
PMC: 8221262.
DOI: 10.1039/d1md00041a.
Hillhouse T, Olson K, Hallahan J, Rysztak L, Sears B, Meurice C
J Pharmacol Exp Ther. 2021; 378(3):287-299.
PMID: 34183434
PMC: 11047085.
DOI: 10.1124/jpet.121.000524.
The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.
Toll L, Cippitelli A, Ozawa A
CNS Drugs. 2021; 35(6):591-607.
PMID: 34057709
PMC: 8279133.
DOI: 10.1007/s40263-021-00821-0.
Crosstalk between Opioid and Anti-Opioid Systems: An Overview and Its Possible Therapeutic Significance.
Gibula-Tarlowska E, Kotlinska J
Biomolecules. 2020; 10(10).
PMID: 32998249
PMC: 7599993.
DOI: 10.3390/biom10101376.
Pain, Motivation, Migraine, and the Microbiome: New Frontiers for Opioid Systems and Disease.
Parker K, Sugiarto E, Taylor A, Pradhan A, Al-Hasani R
Mol Pharmacol. 2020; 98(4):433-444.
PMID: 32958571
PMC: 7562975.
DOI: 10.1124/mol.120.119438.
Biased Opioid Ligands.
Faouzi A, Varga B, Majumdar S
Molecules. 2020; 25(18).
PMID: 32948048
PMC: 7570672.
DOI: 10.3390/molecules25184257.
NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area.
Borruto A, Fotio Y, Stopponi S, Brunori G, Petrella M, Caputi F
Br J Pharmacol. 2019; 177(7):1525-1537.
PMID: 31713848
PMC: 7060370.
DOI: 10.1111/bph.14915.
Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.
Burns J, Kroll D, Feldman D, Kure Liu C, Manza P, Wiers C
Front Psychiatry. 2019; 10:626.
PMID: 31620026
PMC: 6759955.
DOI: 10.3389/fpsyt.2019.00626.
NOP Receptor Agonist Ro 64-6198 Decreases Escalation of Cocaine Self-Administration in Rats Genetically Selected for Alcohol Preference.
Li H, Scuppa G, Shen Q, Masi A, Nasuti C, Cannella N
Front Psychiatry. 2019; 10:176.
PMID: 30984046
PMC: 6450143.
DOI: 10.3389/fpsyt.2019.00176.
NOP-Related Mechanisms in Substance Use Disorders.
Ciccocioppo R, Borruto A, Domi A, Teshima K, Cannella N, Weiss F
Handb Exp Pharmacol. 2019; 254:187-212.
PMID: 30968214
PMC: 6641545.
DOI: 10.1007/164_2019_209.
Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.
Mann A, Mouledous L, Froment C, ONeill P, Dasgupta P, Gunther T
Sci Signal. 2019; 12(574).
PMID: 30914485
PMC: 6934085.
DOI: 10.1126/scisignal.aau8072.
The Nociceptin Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and Cocaine-Induced Conditioned Place Preference in Mice.
Zaveri N, Marquez P, Meyer M, Hamid A, Lutfy K
Front Psychiatry. 2018; 9:638.
PMID: 30555362
PMC: 6281746.
DOI: 10.3389/fpsyt.2018.00638.
A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia.
Khan M, Boileau I, Kolla N, Mizrahi R
Transl Psychiatry. 2018; 8(1):38.
PMID: 29391391
PMC: 5804030.
DOI: 10.1038/s41398-017-0080-8.
Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors.
Shen Q, Deng Y, Ciccocioppo R, Cannella N
Front Psychiatry. 2017; 8:234.
PMID: 29180970
PMC: 5693905.
DOI: 10.3389/fpsyt.2017.00234.
Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats.
de Guglielmo G, Matzeu A, Kononoff J, Mattioni J, Martin-Fardon R, George O
J Pharmacol Exp Ther. 2017; 362(3):378-384.
PMID: 28645915
PMC: 5539589.
DOI: 10.1124/jpet.117.241042.
Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.
Kallupi M, Shen Q, de Guglielmo G, Yasuda D, Journigan V, Zaveri N
Addict Biol. 2017; 23(2):585-595.
PMID: 28635181
PMC: 5740020.
DOI: 10.1111/adb.12513.
Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.
Kallupi M, Scuppa G, de Guglielmo G, Calo G, Weiss F, Statnick M
Neuropsychopharmacology. 2016; 42(3):695-706.
PMID: 27562376
PMC: 5240182.
DOI: 10.1038/npp.2016.171.